Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 45Recurrence 14Lymphoma 6Neoplasms 5Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 4Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Hodgkin Disease 2Glioblastoma 2Amyloidosis 2Wilms Tumor 1Vomiting 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Ototoxicity 1Osteosarcoma 1Obesity 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Vorinostat 2Stem Cell Transplantation 2Rituximab 2Gemcitabine 2Busulfan 2Brentuximab Vedotin 2romidepsin 1pembrolizumab 1molibresib 1entinostat 1copanlisib 1belinostat 1Tacrolimus 1Pyridoxine 1Panobinostat 1Mycophenolic Acid 1Melphalan 1Health Resources 1Granulocyte Colony-Stimulating Factor 1Glutamine 1Filgrastim 1Fibroblast Growth Factor 7 1Dexamethasone 1Cyclophosphamide 1Cryotherapy 1Clofarabine 1Calcium Dobesilate 1CT-P10 1Bortezomib 1BI 6727 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, T-Cell × Dexamethasone × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡